This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Lung Injury, Acute
and you are
between 18 and 80
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This is an early phase (phase IIa), randomized, multi-center study in subjects with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). The purpose of this study is to investigate the safety of GSK2586881 and to determine what effects it has on people with Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). The study has two parts: Part A will be an open-label investigation in five subjects. Part B will be a double-blind, placebo controlled investigation and will involve approximately 60 subjects.

Provided treatments

  • Drug: Dose 1 GSK2586881
  • Drug: Dose 2 GSK2586881
  • Drug: Dose 3 GSK2586881
  • Drug: Dose 4 GSK2586881
  • Drug: Placebo (saline)
Tris trial is registered with FDA with number: NCT01597635. The sponsor of the trial is GlaxoSmithKline and it is looking for 44 volunteers for the current phase.
Official trial title:
A Two Part Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2586881 in Patients With Acute Lung Injury